1. Home
  2. PHGE vs MCVT Comparison

PHGE vs MCVT Comparison

Compare PHGE & MCVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHGE
  • MCVT
  • Stock Information
  • Founded
  • PHGE 2015
  • MCVT 2007
  • Country
  • PHGE Israel
  • MCVT United States
  • Employees
  • PHGE N/A
  • MCVT N/A
  • Industry
  • PHGE Biotechnology: Pharmaceutical Preparations
  • MCVT Finance Companies
  • Sector
  • PHGE Health Care
  • MCVT Finance
  • Exchange
  • PHGE Nasdaq
  • MCVT Nasdaq
  • Market Cap
  • PHGE 11.1M
  • MCVT 11.6M
  • IPO Year
  • PHGE N/A
  • MCVT N/A
  • Fundamental
  • Price
  • PHGE $0.62
  • MCVT $1.99
  • Analyst Decision
  • PHGE Strong Buy
  • MCVT
  • Analyst Count
  • PHGE 2
  • MCVT 0
  • Target Price
  • PHGE $22.50
  • MCVT N/A
  • AVG Volume (30 Days)
  • PHGE 72.5K
  • MCVT 5.6K
  • Earning Date
  • PHGE 11-14-2024
  • MCVT 11-12-2024
  • Dividend Yield
  • PHGE N/A
  • MCVT N/A
  • EPS Growth
  • PHGE N/A
  • MCVT N/A
  • EPS
  • PHGE N/A
  • MCVT 0.05
  • Revenue
  • PHGE N/A
  • MCVT $3,234,265.00
  • Revenue This Year
  • PHGE N/A
  • MCVT N/A
  • Revenue Next Year
  • PHGE N/A
  • MCVT N/A
  • P/E Ratio
  • PHGE N/A
  • MCVT $40.51
  • Revenue Growth
  • PHGE N/A
  • MCVT N/A
  • 52 Week Low
  • PHGE $0.48
  • MCVT $1.75
  • 52 Week High
  • PHGE $8.55
  • MCVT $3.88
  • Technical
  • Relative Strength Index (RSI)
  • PHGE 45.57
  • MCVT 51.73
  • Support Level
  • PHGE $0.56
  • MCVT $1.91
  • Resistance Level
  • PHGE $0.69
  • MCVT $2.05
  • Average True Range (ATR)
  • PHGE 0.08
  • MCVT 0.06
  • MACD
  • PHGE 0.01
  • MCVT 0.01
  • Stochastic Oscillator
  • PHGE 28.57
  • MCVT 52.38

About PHGE BiomX Inc. COmmon Stock

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.

About MCVT Mill City Ventures III Ltd.

Mill City Ventures III Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions primarily to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that they provide are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.

Share on Social Networks: